Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis
Cardiorenal Medicine · 14.05.2026 · 16 (1) · 220-236
DOI: 10.1159/000551330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiorenal Medicine, online erschienen am 14.05.2026. Verfasst von Wei Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shenzhen Bao'an Authentic Traditional Chinese Medicine Therapy Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Kidney, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of agents initially developed for glycemic control in type 2 diabetes mellitus. Beyond their glucose-lowering effects, accumulating clinical evidence has demonstrated significant cardiorenal protective benefits in patients with chronic kidney disease (CKD), irrespective of diabetic status. Cardiac and renal fibrosis are central pathological processes contributing to CKD progression and cardiovascular dysfunction. However, the mechanisms underlying the anti-fibrotic effects of SGLT2 inhibitors remain incompletely understood. Summary: This review summarizes current experimental and clinical evidence regarding the role of SGLT2 inhibitors in modulating cardiac and renal fibrosis. We discuss their potential mechanisms, including hemodynamic regulation, metabolic reprogramming, attenuation of oxidative stress and inflammation, inhibition of pro-fibrotic signaling pathways, and modulation of cellular crosstalk within the cardiorenal axis. Emerging insights from molecular and translational studies are integrated to clarify how SGLT2 inhibitors may exert anti-fibrotic effects beyond glycemic control. Key Messages: SGLT2 inhibitors confer cardiorenal protection that extends beyond glucose lowering and involves multifaceted anti-fibrotic mechanisms. Understanding these molecular and cellular pathways may provide new therapeutic perspectives for targeting fibrosis in CKD and cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Shenzhen Bao'an Authentic Traditional Chinese Medicine Therapy Hospital, Shenzhen, China.
- Preventive Treatment Department, The Fourth Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
- Preventive Treatment Department, Shenzhen Bao'an Authentic Traditional Chinese Medicine Therapy Hospital, Shenzhen, China.
- Department of Nephrology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
- Acupuncture Department, Shenzhen Bao'an Authentic Traditional Chinese Medicine Therapy Hospital, Shenzhen, China, 15242440670@163.com.
- Department of Liver Disease, Nanshan District Traditional Chinese Medicine Hospital, Shenzhen, China, doncare6661@outlook.com.
Zitieren
APA
Huang, W., Guan, T., Yan, Z., Cui, Y., Bi, S., Wu, M., & Yuan, D. (2026). Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis. Cardiorenal Medicine, 16(1), 220-236. https://doi.org/10.1159/000551330
Vancouver
Huang W, Guan T, Yan Z, Cui Y, Bi S, Wu M, et al. Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis. Cardiorenal Medicine. 2026;16(1):220-236. doi:10.1159/000551330
BibTeX
@article{Huang2026,
author = {Huang, Wei and Guan, Tianxiang and Yan, Ziyou and Cui, Yuanwu and Bi, Shanrong and Wu, Mingxia and Yuan, Dongkai},
title = {Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis},
journal = {Cardiorenal Medicine},
year = {2026},
volume = {16},
number = {1},
pages = {220--236},
doi = {10.1159/000551330}
}
EUVIMED